RU58841 is the only thing that worked for me, a DUPA sufferer Treatment 7/10/2025
RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity 2 Year Update: 24 months of Dutasteride 1mg Daily and 2.5-5mg Oral Minoxidil Daily on Diffuse Unpatterned Alopecia
A user experienced significant hair regrowth after 24 months using 1mg daily Dutasteride and 2.5-5mg oral Minoxidil for diffuse unpatterned alopecia. The discussion covers treatment effectiveness, side effects, and comparisons with Finasteride.
community Why is diffuse thinning so hard to recover, 3 plus years on meds!
The user has been using finasteride and minoxidil for over three years, switched to oral minoxidil, and recently started dutasteride and dermarolling but still experiences thin hair. They are seeking suggestions for improving their hair condition.
community Nearly Two Years of Min/Fin — 25M
The user has been using minoxidil and finasteride for nearly two years, seeing some prevention of further hair loss and possible regrowth. Many suggest trying dutasteride or considering a hair transplant as the next step.
community 1.5 Year - Bad Results (HT, FIN, MINO, PRP, etc)
A user shared their disappointing results after 1.5 years of hair treatments, including a hair transplant, finasteride, minoxidil, PRP, vegan shampoo, and more. They are considering switching to dutasteride, oral minoxidil, and improving their microneedling routine.
community 24M - Dut + Min not working. How cooked am I?
A 24-year-old is struggling with hair loss despite using treatments like dutasteride, oral minoxidil, RU58841, and considering a hair transplant. They are advised to continue medication, possibly increase dosages, and explore additional treatments like tretinoin and tacrolimus.
community I don’t know what to do at this point
A 21-year-old woman with female pattern baldness has tried minoxidil, red light therapy, and supplements without success. She is considering spironolactone and seeking medical advice.
Related Research
6 / 6 results
research FEATURES OF THE DEVELOPMENT OF ACUTE DIFFUSE TELOGEN EFFLUVIUM IN PATIENTS WITH POST-COVID SYNDROME
Treating post-COVID hair loss leads to full recovery, while not treating it often results in ongoing symptoms.
research Modern Ideas About Diffuse Alopecia
This article reviews the causes, development, and treatment of diffuse alopecia, describing various external therapies and physiotherapy techniques.
research Pharmacotherapy for diffuse alopecia
In this study, the use of Selencin, both in tablet and peptide lotion form, over two months showed significant improvements in reducing hair loss and restoring hair structure and volume in patients with diffuse alopecia, with effects persisting up to four months after treatment.
research EXPERIENCE IN TREATMENT OF DIFFUSE HAIR LOSS
In this article, the authors concluded that despite diverse causes of diffuse hair loss, modern therapies can effectively manage the condition without side effects, as demonstrated in two clinical cases of telogen effluvium.
research Using high-intensity phototechnology as a method of treating mild to severe diffuse alopecia
This study found that combining fractional laser therapy, intravenous blood irradiation, and minoxidil significantly improved the psycho-emotional state and quality of life in patients with diffuse telogen effluvium, performing better than individual treatments alone, as measured by the DIQOL index.
research Complex application of high-intensity phototechnologies in the treatment of diffuse alopecia
In this study, a combined treatment method using fractional laser therapy, intravenous blood irradiation, and minoxidil significantly improved hair loss in patients with diffuse telogenetic alopecia compared to other treatments, showing a 36.9% improvement in mild cases and a 70.8% improvement in severe cases.